Abstract
Rheumatoid arthritis (RA) is a chronic disease with a complex underlying pathology and varied presentation in patients. Several novel biologic disease-modifying antirheumatic drugs have become available for the treatment of RA. Agents in late-stage clinical trials include golimumab and certolizumab, which are anti-tumor necrosis factor (TNF)-alpha agents; ocrelizumab, an anti-CD20 agent; and tocilizumab, an inhibitor of interleukin-6. As treatment options for RA expand, nursing care will play an increasingly important role in empowering patients through interventions such as patient education and adverse effect management.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / pharmacology
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / nursing
-
Arthritis, Rheumatoid / physiopathology
-
Education, Continuing
-
Humans
-
Interleukin-6 / antagonists & inhibitors
-
Nurse's Role
-
Patient Education as Topic
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Interleukin-6
-
Tumor Necrosis Factor-alpha
-
golimumab
-
ocrelizumab
-
tocilizumab